Rev. OFIL 2017, 27;4:327-333
Fecha de recepción: 07/12/2016 – Fecha de aceptación: 02/03/2017
Ruiz Jiménez MM1, García Molina O1, Martínez Martínez JA2, de la Rubia Nieto MA1
1 Hospital Clínico Universitario Virgen de la Arrixaca. Servicio de Farmacia. Murcia (España)
2 Departamento de Farmacología de la Facultad de Medicina de la Universidad de Murcia (España)
María del Mar Ruiz Jiménez
Hospital Universitario Virgen de la Arrixaca
(Servicio de Farmacia)
Ctra. Cartagena-Madrid, s/n
30120 El Palmar (Murcia)
Correo electrónico: email@example.com
Este trabajo ha sido enviado previamente en forma de póster al 22th Congress of the EAHP celebrado
en Cannes (Francia) del 22 al 24 de marzo de 2017
Objective: To analyze and compare the effectiveness and safety of treatment with anti-TNFα agents (adalimumab, etanercept and infliximab) in elderly patients (over 65 years) with rheumatoid arthritis (RA).
Material and methods: Descriptive and retrospective study in a tertiary hospital with 800 beds. All patients aged over 65 years diagnosed with RA treated with adalimumab, etanercept or infliximab, were included since 2013 to 2015. The data analysis was performed using SPSS®.
Results: The sample was 47 patients. 85% were women. 31.9% (n=15) treated with infliximab, 29.8% (n=14) with etanercept and 38.3% (n=18) with adalimumab. The mean age was 71.7±5.2 years. The main causes of treatment discontinuation were: remission with 13.3% for infliximab and 11.1% for adalimumab, therapeutic failure with 14.3% for etanercept and 16.6% for adalimumab and adverse event with 11.1% for adalimumab. The median survival was 11.4 years (95% CI) for infliximab and 9.6 years (95% CI) for adalimumab. For etanercept the median was not reached at the time of the cut. Survival at 5 years was 73% for infliximab, 75% for etanercept and 62% for adalimumab (log-rank p=0.613; Breslow p=0.927).The main adverse effects observed were infections and respiratory disorders for three drugs.
Key Words: Arthritis Rheumatoid, effectiveness, safety, elderly.